MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14712598.2020.1761957

Медицинская библиотека · Expert opinion on biological therapy · 2020

One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study.

Chimenti Maria Sole, Fonti Giulia Lavinia, Conigliaro Paola, Sunzini Flavia, Scrivo Rossana, Navarini Luca, Triggianese Paola, Peluso Giusy, Scolieri Palma, Caccavale Rosalba, Picchianti Diamanti Andrea, De Martino Erica, Salemi Simonetta, Birra Domenico, Altobelli Alessio, Paroli Marino, Bruzzese Vincenzo, Laganà Bruno, Gremese Elisa, Conti Fabrizio, Afeltra Antonella, Perricone Roberto

СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Secukinumab (SEC) is effective for ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in randomized trials, but real-life data are lacking.

RESEARCH DESIGN AND

METHODS

Real-life, prospective observational study on 169 consecutive outpatients at baseline (T0) and at 6 (T6) and 12 months (T12) after starting SEC (39 AS, 23%; 130 PsA, 77%).

RESULTS

Significant improvement was seen at T6 and T12 for all clinical variables, including TJC, SJC, ESR, CRP, DAPSA, ASDAS-CRP, and BASDAI, as well as in patient-reported outcomes like VAS-pain. By multivariable regression analysis, in AS patients high BASDAI at T0 correlated with diagnostic delay (R2 = 0.4; p = 0.009) and peripheral joint involvement (R2 = 0.4; p = 0.04). During follow-up, reduction of BASDAI positively correlated with high ESR (R2 = 0.65; p = 0.04). ASDAS-CRP at T0 positively correlated with high ESR (R2 = 0.34; p = 0.004). Reduction of ASDAS-CRP from T0 to T6 correlated with current smoking status (R2 = 0.42; p = 0.003). In PsA patients, reduction of DAPSA score from T0 to T12 is negatively correlated with the presence of metabolic syndrome (R2 = 0.41; p = 0.0025). SEC was well tolerated; 10 patients discontinued treatment for non-severe adverse events.

CONCLUSIONS

Secukinumab is effective and safe in patients with AS and PsA in a real-life setting.

Для цитирования: Chimenti Maria Sole, Fonti Giulia Lavinia, Conigliaro Paola, Sunzini Flavia, Scrivo Rossana, Navarini Luca, Triggianese Paola, Peluso Giusy, Scolieri Palma, Caccavale Rosalba, Picchianti Diamanti Andrea, De Martino Erica, Salemi Simonetta, Birra Domenico, Altobelli Alessio, Paroli Marino, Bruzzese Vincenzo, Laganà Bruno, Gremese Elisa, Conti Fabrizio, Afeltra Antonella, Perricone Roberto. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study.. Expert opinion on biological therapy. 2020. DOI: 10.1080/14712598.2020.1761957.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.